2025
SJR Q2
JCR Q3 · 1,8
183 matched articles
SCIE
Journal detail
In Vivo
- Publisher
- International Institute of Anticancer Research
- Country
- Greece · Western Europe
- Type
- journal
- ISSN
-
0258851X17917549
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,536
- Quartile Q2
- H-Index 77
- Cites/doc 1,94
- Docs (3y) 1.124
- Cites (3y) 2.228
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,8
- 5Y JIF 1,8
- JCI 0,46
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Biochemistry, Genetics and Molecular Biology (miscellaneous) Q2
- Cancer Research Q4
- Medicine (miscellaneous) Q2
- Pharmacology Q3
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Medicine, Research & Experimental
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,536 | 1,8 | 1,8 | 0,46 | Q3 | 77 |
| 2024 | Q2 | Q3 | 0,562 | 1,8 | 1,8 | 0,47 | Q3 | 74 |
| 2023 | Q2 | Q3 | 0,555 | 1,8 | 1,9 | 0,48 | Q3 | 74 |
| 2022 | Q2 | Q4 | 0,54 | 2,3 | 2,2 | 0,49 | Q3 | 74 |
| 2021 | Q2 | Q4 | 0,522 | 2,4 | 2,3 | 0,52 | Q3 | 74 |
| 2020 | Q2 | Q4 | 0,545 | 2,2 | 2,1 | 0,54 | Q3 | 74 |
| 2019 | Q2 | Q4 | 0,458 | 1,5 | 1,4 | 0,56 | Q3 | 74 |
| 2018 | — | Q3 | — | 1,6 | 1,3 | 0,56 | Q3 | — |
| 2017 | Q2 | Q4 | 0,409 | 1,1 | 1,1 | 0,41 | Q3 | 74 |
| 2016 | Q3 | Q4 | 0,382 | 1 | 1,1 | — | — | 74 |
| 2015 | Q3 | Q4 | 0,401 | 0,8 | 1 | — | — | 74 |
| 2014 | Q3 | Q4 | 0,406 | 1 | 1,1 | — | — | 74 |
| 2013 | Q2 | Q4 | 0,421 | 1,1 | 1,3 | — | — | 74 |
| 2012 | Q2 | Q3 | 0,419 | 1,2 | 1,3 | — | — | 74 |
| 2011 | Q2 | Q3 | 0,432 | 1,3 | 1,1 | — | — | 74 |
| 2010 | Q2 | Q3 | 0,442 | 1,2 | 1,1 | — | — | 74 |
| 2009 | — | Q3 | — | 1,2 | 1,2 | — | — | — |
| 2008 | — | Q4 | — | 1 | 1,1 | — | — | — |
| 2007 | — | Q4 | — | 1,1 | 1,1 | — | — | — |
| 2006 | — | Q3 | — | 1,3 | — | — | — | — |
| 2005 | — | Q3 | — | 1 | — | — | — | — |
| 2004 | — | Q4 | — | 0,8 | — | — | — | — |
| 2003 | — | Q4 | — | 0,8 | — | — | — | — |
| 2002 | — | Q3 | — | 1,1 | — | — | — | — |
| 2001 | — | Q3 | — | 1 | — | — | — | — |
| 2000 | — | Q3 | — | 1 | — | — | — | — |
| 1999 | — | Q3 | — | 0,8 | — | — | — | — |
| 1998 | — | Q3 | — | 0,7 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 136/191 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 138/195 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 129/189 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 103/136 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 116/139 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 113/140 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 111/139 |
| 2018 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q3 | 102/136 |
| 2017 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 114/133 |
| 2016 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 107/128 |
| 2015 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 109/124 |
| 2014 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 106/123 |
| 2013 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 95/124 |
| 2012 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 87/121 |
| 2011 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 76/112 |
| 2010 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 76/106 |
| 2009 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 67/93 |
| 2008 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 67/83 |
| 2007 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 64/81 |
| 2006 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 52/76 |
| 2005 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 52/72 |
| 2004 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 57/71 |
| 2003 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 56/72 |
| 2002 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 50/74 |
| 2001 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 50/75 |
| 2000 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 47/74 |
| 1999 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 47/76 |
| 1998 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 38/72 |